Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

Rybelsus 4 mg Tablet

Active Ingredient:
semaglutide
Company:  
Novo Nordisk Limited See contact details
ATC code: 
A10BJ06
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Letters to HCPs
{arrow_left}
{arrow_right}

Important information for Healthcare Professionals

{pdf_link}

DHPC Letter- Rybelsus (oral semaglutide): risk of medication error due to introduction of new formulation with increased bioavailability

{healthcare_pro_orange} For Healthcare Professionals

The purpose of the communication is to notify healthcare professionals (HCPs) of a change in formulation of Rybelsus. Rybelsus tablets will be replaced with a new formulation with increased bioavailability, which is bioequivalent to the initial formulation.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Novo Nordisk Limited
Company image
Address
3 City Place, Beehive Ring Road, Gatwick, West Sussex, RH6 0PA
Telephone
+44 (0)1293 613555
Fax
+44 (0)1293 613535
Customer Care direct line
+44 (0)800 023 2573
Medical Information Direct Line
+44 (0)800 023 2573
Medical Information e-mail
[email protected]
WWW
http://www.novonordisk.co.uk